Cancer Institute A national cancer institute
designated cancer center
Email this profile
Portrait View Larger

Chris Cartwright, MD

Academic Appointments

  • Professor of Medicine (Gastroenterology and Hepatology)

Contact Information

  • Clinical Offices
    Stanford Gastroenterology 900 Blake Wilbur Dr Garden Level MC 5355 Palo Alto, CA 94304
    Tel Work (650) 736-5555 Fax (650) 498-6323
  • Academic Offices
    Personal Information
    Email Tel (650) 725-8464
    Alternate Contact
    Diane Ayala GI Administrative Assistant Tel Work 650-725-6511
    Not for medical emergencies or patient use

Professional Overview

Clinical Focus

  • Gastroenterology
  • Inflammatory Bowel Diseases

Administrative Appointments

  • Director, Program for Inflammatory Bowel Diseases, Stanford University School of Medicine (1989 - present)

Honors and Awards

  • Outstanding AGA Women in Science, American Gastroenterological Association (2008)
  • Premier Physician Award, Crohn's & Colitis Foundation of America - Greater Bay Area Chapter (2000)
  • Member, American Society for Clinical Investigation (1995)

Professional Education

BS: Stanford University, Biology (1973)
MD: University of Utah, Medicine (1978)
Internship: UCSD Medical Center CA (1979)
Residency: UCSD Medical Center CA (1981)
Fellowship: UCSD Medical Center CA (1984)
Research Associate: The Salk Institute, Cancer Biology (1989)
View All 9

Community and International Work



Graduate and Fellowship Program Affiliations

Scientific Focus

Current Research and Scholarly Interests

Research in my laboratory focuses on molecular mechanisms of intestinal cell growth control. A primary focus is on function and regulation of the Src family of tyrosine kinases in normal cells, and their deregulation in cancer cells. Molecular, cellular and physiologic approaches are used to explore basic questions about growth regulation. Areas of active investigation include studies of Src function in cell cycle progression, proliferation, differentiation, adhesion, survival and malignant transformation; discovery of endogenous inhibitors of Src kinases; analysis of inhibitor function in cell growth control and apoptosis; and exploration of new drug therapy for colon cancer. Our recent discovery of a Src inhibitor, RACK1, which works both to inhibit growth (by suppressing Src activity at G1 and mitotic checkpoints) and to induce death of colon cells, could be exploited for development of new and more powerful and selective strategies for treatment of human colon cancer.


Publication tag cloud

Publication Topics

View All 24

Stanford Medicine Resources:

Footer Links: